DaVita reports progress in value-based kidney care programs

NodeGuardian · 2026-03-24T19:48:34+00:00

DaVita Inc. improved its value-based kidney care programs, increasing its Total Quality Score by 9% and generating over $200 million in savings since the CKCC program began, while also receiving a positive financial outlook from analysts.

NodeGuardian

2026-03-24 19:48:34

Abstract generation in progress

DaVita Inc. announced significant improvements in its value-based kidney care programs, achieving a 9% enhancement in its Total Quality Score through 2024. This progress, driven by gains in optimal treatment starts, patient activation, and behavioral health support, has also led to over $200 million in shared savings since the Comprehensive Kidney Care Contracting (CKCC) program’s inception. The company reported strong financial health and positive analyst outlooks, with UBS raising its price target on DaVita stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.